Bio-Techne (TECH)
NASDAQ:TECH
Want to see TECH full AI Analyst Report?
TECH Stock Chart & Stats
$59.23
-$0.13(-0.17%)
At close: 4:00 PM EST
$59.23
-$0.13(-0.17%)
Day’s Range― - ―
52-Week Range$43.20 - $72.16
Previous CloseN/A
Volume102.39K
Average Volume (3M)3.08M
Market Cap
$8.81B
Enterprise Value$8.69B
Total Cash (Recent Filing)$209.82M
Total Debt (Recent Filing)$290.32M
Price to Earnings (P/E)82.9
Beta0.96
Next Earnings
Aug 11, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield0.54%
Share Statistics
EPS (TTM)0.71
Shares Outstanding156,568,760
10 Day Avg. Volume2,976,153
30 Day Avg. Volume3,079,255
Financial Highlights & Ratios
PEG Ratio-1.95
Price to Book (P/B)4.22
Price to Sales (P/S)6.64
P/FCF Ratio31.59
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue7.18
Enterprise Value/Gross Profit11.05
Enterprise Value/Ebitda33.69
Forecast
1Y Price Target
$61.20Price Target Upside3.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)1.93
Revenue Forecast (FY)$1.21B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained operating cash flow that exceeds operating profit and strong free cash flow growth provide durable funding for R&D, instrument attach strategies, and working capital. This cash cushion supports execution through cyclical downturns and funds strategic initiatives without heavy reliance on external financing.
Low Leverage / Solid Balance SheetVery low leverage and a meaningful equity base give the company financial flexibility to invest in scale-up, absorb lumpy orders, and sustain operations during industry slowdowns. This balance sheet strength reduces refinancing risk and preserves optionality for capex or acquisitions over the medium term.
High-value Growth PlatformsRapid COMET growth, a record backlog and initial China installation point to a scalable instrument-plus-consumables flywheel in spatial biology. Combined with strong GMP protein demand and regulatory wins, these high-value platforms should drive recurring attach revenue and higher-margin growth over coming years.
Bears Say
Sharp Revenue DeclineA near-40% TTM revenue drop represents a material scale reduction that can erode operating leverage and slow investments. Even with cash strength, restoring prior growth rates requires end-market recovery and conversion of backlog, making near-term topline improvement uncertain and dependent on external funding trends.
Compressed ProfitabilitySustained margin compression versus prior years reflects mix shifts, volume deleverage and timing effects. Lower net margins reduce retained earnings and the ability to self-fund growth or cushion shocks. Durable margin recovery hinges on rebalancing product mix toward higher-margin platforms and consistent demand.
Biotech Funding & Timing CyclicalityHeavy exposure to early-stage biotech funding cycles and large, lumpy OEM or fast-track orders makes revenue volatile and visibility poor. Timing-driven swings can persist for multiple quarters, delaying sustainable organic growth and complicating capacity and cost planning for consumables and instrument rollouts.
Bio-Techne News
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $43.20 and its highest was $72.16 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $8.81B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Aug 11, 2026 which is in 47 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on May 06, 2026. The company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.534 by -$0.004.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.54%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.52.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 156,568,760 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.53 in its last earnings report, missing expectations of $0.534. Following the earnings report the stock price went down -16.364%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Techne Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$61.20 (3.33% Upside)
$61.20 (3.33% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 327.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $320.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.6%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.46%
12-Months-Change
Fundamentals
Return on Equity
5.49%
Trailing 12-Months
Asset Growth
-3.54%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, is a global enterprise specializing in the development, production, and distribution of specialized life science tools, instrumentation, and support solutions for both research and clinical diagnostic markets. The company is organized into two key business units: Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment manufactures a broad array of biological components, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, which are instrumental across life science research, diagnostic applications, and advancements in cell and gene therapy. This division further provides sophisticated proteomic analysis platforms, encompassing automated western blot and multiplexed ELISA workflows, coupled with relevant instrumentation and immunoassay kits designed for precise protein quantification in various biological fluids. The Diagnostics and Genomics segment is dedicated to developing and manufacturing diagnostic offerings, such as controls, calibrators, and specific diagnostic assays tailored for regulated markets. Its portfolio extends to innovative exosome-based molecular diagnostic tests, advanced in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and a variety of genetic and oncology kits for both research and clinical use. Additionally, this segment supplies products vital for genetic carrier screening, oncology diagnostics, molecular controls, and general research, alongside instrumentation and process controls for hematology, blood chemistry, gas analysis, and coagulation diagnostic applications. Its comprehensive product suite is offered under prominent brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen. Founded in 1976 as Techne Corporation, the company adopted its current name, Bio-Techne Corporation, in November 2014.
TECH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong execution in high-value growth vectors (Spatial Biology/COMET, GMP proteins excl. timing impacts, Proteomic Analysis instruments, large pharma strength and four consecutive quarters of China growth), solid sequential margin improvement and robust cash generation. Offsetting these positives were a 2% organic revenue decline, continued weakness in emerging/early-stage biotech spending, timing headwinds from two fast-track cell therapy customers and an OEM order, and YoY mix-related margin pressure. Management expects near-term organic revenue to be roughly flat but positions the business for an inflection in fiscal 2027 as funding improvements translate to customer spending.View all TECH earnings summariesTECH Net revenue Breakdown
71.35% Protein Sciences
28.39% Diagnostics and Genomics
-0.08% Intersegment
0.34% Other revenue
TECH Stock 12 Month Forecast
Average Price Target
$61.20
▲(3.33% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Jazz Pharmaceuticals
―
Rhythm Pharmaceuticals
―
Roivant Sciences
―
Ownership Overview
0.30% Insiders
41.71% Mutual Funds
21.62% Other Institutional Investors
9.54% Public Companies and
Individual Investors